公开(公告)号：US12110337B2

公开(公告)日：2024-10-08

申请号：US17045143

申请日：2019-04-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Li-Sheng Lu ,  Mark J. Selby ,  Alan J. Korman ,  Shrikant Deshpande ,  Mohan Srinivasan ,  Jun Zhang ,  Haichun Huang ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina Deyanova

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K39/39541 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92

Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

公开(公告)号：US20210155703A1

公开(公告)日：2021-05-27

申请号：US17045143

申请日：2019-04-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Li-Sheng Lu ,  Mark J. Selby ,  Alan J. Korman ,  Shrikant Deshpande ,  Mohan Srinivasan ,  Jun Zhang ,  Haichun Huang ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K45/06

Abstract: This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.